Tools
Tools
Singh, Bhagteshwar, Ryan, Hannah, Kredo, Tamara, Chaplin, Martha and Fletcher, Tom (2021) 'Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19'. The Cochrane Database of Systematic Reviews, Vol 2021, Issue 2, CD013587.
|
Text
Singh_et_al-2021-Cochrane_Database_of_Systematic_Reviews.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview |
Abstract
Background
The coronavirus disease 2019 (COVID‐19) pandemic has resulted in substantial mortality. Some specialists proposed chloroquine (CQ) and hydroxychloroquine (HCQ) for treating or preventing the disease. The efficacy and safety of these drugs have been assessed in randomized controlled trials.
Objectives
To evaluate the effects of chloroquine (CQ) or hydroxychloroquine (HCQ) for
1) treating people with COVID‐19 on death and time to clearance of the virus;
2) preventing infection in people at risk of SARS‐CoV‐2 exposure;
3) preventing infection in people exposed to SARS‐CoV‐2.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Current Controlled Trials (www.controlled‐trials.com), and the COVID‐19‐specific resources www.covid‐nma.com and covid‐19.cochrane.org, for studies of any publication status and in any language. We performed all searches up to 15 September 2020. We contacted researchers to identify unpublished and ongoing studies.
Selection criteria
We included randomized controlled trials (RCTs) testing chloroquine or hydroxychloroquine in people with COVID‐19, people at risk of COVID‐19 exposure, and people exposed to COVID‐19.
Adverse events (any, serious, and QT‐interval prolongation on electrocardiogram) were also extracted.
Data collection and analysis
Two review authors independently assessed eligibility of search results, extracted data from the included studies, and assessed risk of bias using the Cochrane ‘Risk of bias’ tool. We contacted study authors for clarification and additional data for some studies. We used risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CIs). We performed meta‐analysis using a random‐effects model for outcomes where pooling of effect estimates was appropriate.
| Item Type: | Article |
|---|---|
| Subjects: | QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials WA Public Health > WA 105 Epidemiology WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.1002/14651858.CD013587.pub2 |
| Depositing User: | Christianne Esparza |
| Date Deposited: | 25 Feb 2021 09:40 |
| Last Modified: | 25 Feb 2021 09:41 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/17057 |
Statistics
Actions (login required)
 |
Edit Item |